Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-masked, Parallel, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of SJP-0132 Eye Drops Compared With Placebo in Chinese Patients With Dry Eye Disease
This study will evaluate the safety and efficacy of SJP-0132 in Chinese Patients with Dry Eye.
Patients will be randomly assigned to receive either SJP-0132 or placebo.
100 Clinical Results associated with Senju Pharmaceutical Beijing Co. Ltd.
0 Patents (Medical) associated with Senju Pharmaceutical Beijing Co. Ltd.
100 Deals associated with Senju Pharmaceutical Beijing Co. Ltd.
100 Translational Medicine associated with Senju Pharmaceutical Beijing Co. Ltd.